CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 91 enrolled
Drug / intervention
Immunohistochemical stainingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05257057
NCT05257057N/ACompleted

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

WellSpan Health·observational·Posted Feb 25, 2022·Updated Mar 28, 2025

In Brief

An observational study evaluating Immunohistochemical staining for Lynch Syndrome and 4 related conditions. Completed, enrolled 91 participants across 1 site.

Detailed Summary

Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial cancer among patients with endometrial hyperplasia (40% risk of pre-existing occult cancer with endometrial intraepithelial neoplasia), it is hypothesized that a diagnosis of endometrial hyperplasia may herald on-going risk of harboring a Lynch Syndrome gene mutation. The purpose of this study is to examine endometrial hyperplasia specimens and compare the frequency of Lynch Syndrome gene mutations between endometrial hyperplasia and endometrial cancer subjects. This will provide a rationale and opportunity for earlier screening, and reduce colon cancer morbidity and mortality secondary to the Lynch syndrome gene.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 25, 2022
Enrollment StartMay 8, 2019
Primary CompletionJun 2, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 4.4 years ago

Interventions

Immunohistochemical stainingother

Immunohistochemistry will be performed on the endometrial tissue specimens